Not so NICE for Avastin
The U.K.'s National Institute for Health and Clinical Excellence terminates its review of Roche/Genentech's Avastin (bevacizumab) for first-line metastatic breast cancer because the sponsor failed to submit sufficient evidence, the regulatory body announces June 25. Avastin received approval for a breast cancer indication in the U.S. in February. NICE also stopped its review of Avastin for the first-line treatment of metastatic or recurrent non-small cell lung cancer, another indication approved in the U.S. Review of Bristol-Myers Squibb/ImClone/Merck KGaA's Erbitux (cetuximab) for second-line treatment of colorectal cancer was similarly terminated due to the failure to submit sufficient evidence
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.